A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament
Completed
PriCara, Unit of Ortho-McNeil, Inc.
Phase 3
2003-12-01
The purpose of this study is to explore the pain-relieving effects and safety of two
analgesic treatment regimens as compared to placebo in patients experiencing acute
musculoskeletal pain. Patients who are experiencing at least moderate acute musculoskeletal
pain from an ankle sprain severe enough to require prescription pain relief medication will
be randomized to receive either tramadol HCl/acetaminophen, hydrocodone
bitartrate/acetaminophen or placebo.
A Study of the Efficacy and Safety of Tramadol HCl/Acetaminophen, Hydrocodone Bitartrate/Acetaminophen and Placebo in Patients With Pain From an Ankle Sprain With a Partial Torn Ligament
Completed
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3
2003-12-01
The purpose of this study is to explore the pain-relieving effects and safety of two
analgesic treatment regimens as compared to placebo in patients experiencing acute
musculoskeletal pain. Patients who are experiencing at least moderate acute musculoskeletal
pain from an ankle sprain severe enough to require prescription pain relief medication will
be randomized to receive either tramadol HCl/acetaminophen, hydrocodone
bitartrate/acetaminophen or placebo.
Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain
Completed
Zogenix, Inc.
Phase 3
2010-03-01
The purpose of the study is to evaluate the safety and efficacy of Hydrocodone Bitartrate
controlled-release capsules in subjects with chronic low back pain.
Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain
Completed
Zogenix, Inc.
Phase 3
2010-05-01
This Phase 3, multi-center study will evaluate the long-term safety and tolerability of
hydrocodone bitartrate controlled release capsule (HC-CR) at daily doses of 40 mg or more in
subjects with moderate to severe chronic pain. Long-term maintenance of HC-CR efficacy will
be evaluated.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
